Stock BIOV BIOVAXYS TECHNOLOGY CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Company BioVaxys Technology Corp.

Equities

BIOV

CA09076M1014

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange
Other stock markets
 14:35:20 03/05/2024 BST 		5-day change 1st Jan Change
0.08 CAD 0.00% Intraday chart for BioVaxys Technology Corp. +6.67% +60.00%
04-30 BioVaxys Technology Corp. Appoints Christopher Cherry as Chief Financial Officer CI
04-10 Biovaxys and SpayVac-For-Wildlife, Inc. Announce Launch of Field Trial for Large-Scale Immunocontraception in the Commercial Aquatic Farming Industry CI

Business Summary

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

Managers

Managers TitleAgeSince
James Passin FOU
 Founder 52 -
Kenneth Kovan FOU
 Founder - -
David Berd FOU
 Founder 79 29/09/20
Craig Loverock BRD
 Director/Board Member 53 07/09/22
Lachlan McLeod SEC
 Corporate Secretary 37 05/07/20

Members of the board

Members of the board TitleAgeSince
James Passin FOU
 Founder 52 -
Anthony Dutton BRD
 Director/Board Member 66 28/04/22
Craig Loverock BRD
 Director/Board Member 53 07/09/22
David Wang BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 210,813,161 196,885,828 ( 93.39 %) 0 93.39 %

Shareholders

NameEquities%Valuation
James Passin
11.15 %
16,177,333 11.15 % 905 931 $
Kenneth Kovan
5.067 %
7,352,862 5.067 % 411 760 $
David Wang
1.029 %
1,492,575 1.029 % 83 584 $
Anthony Dutton
0.1723 %
250,000 0.1723 % 14 000 $
Craig Loverock
0.000000 %
0 0.000000 % - $

Company contact information

BioVaxys Technology Corp.

146 Thirtieth Street Suite 100

M8W 3C4, Etobicoke

+

http://www.biovaxys.com
address BioVaxys Technology Corp.(BIOV)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOVAXYS TECHNOLOGY CORP. Stock BioVaxys Technology Corp.
+60.00% 12.33M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BIOV Stock
  4. Company BioVaxys Technology Corp.